

CURRICULUM VITAE

Name, Title: Mozghan Dorkhan, MD, PhD

Gender: Female

Date of birth: April 6th, 1970

Nationality: Swedish, Iranian

Work address: Malmö University Hospital, Diabetes and Endocrinology department

Phone: +46-40-332234

e-mail: mozhgan.dorkhan@med.lu.se

1. Degrees:

MD, Lund University, 1997

PhD, Lund University, 2008, Supervisor: Professor Leif Groop, title: Assessment and Treatment of Impaired Insulin Secretion and Action in Type 2 Diabetes

Specialist in Internal Medicine, 2008, Malmö University Hospital

Specialist in Diabetes and Endocrinology, 2009, Malmö University Hospital

2. Present position:

Consultant, department of Diabetes and Endocrinology, Malmö University Hospital, 50%
Post. Doc., Clinical Research Centre, Malmö, Project leader ANDiS (All New Diabetics in Scania) 50%

3. Previous positions:

Resident in Internal Medicine and Diabetes/Endocrinology, Malmö University Hospital

PhD student, Lund University

4. Postdoc periods:

Post. Doc., Clinical Research Centre, Malmö, since January 2009, Project leader ANDiS (All New Diabetics in Scania) 50%

5. Supervised postdocs and PhD-students:

Co-supervisor for Maja Ekman, main supervisor Ass. Prof. Martin Ridderstråle

Clinical mentor and co-supervisor for David Buchebner

6. Teaching activities, including pedagogic training:

Regular teaching of medical students

Arranging internal educational activities at the department of Diabetes and Endocrinology

Arranging national grad/post grad courses in Diabetes and Endocrinology

Member of Ajman project (educational response during development of diabetes care in Ajman, United Arab Emirates)

Speaker for drug companies (Eli-Lilly, Novartis, Sanofi-Aventis)

7. Leadership and administrative merits:

Project leader ANDiS (All New Diabetics in Scania) since January 2009

Responsible for several internal educational activities at the department of Diabetes and Endocrinology, Malmö University Hospital

Research coordinator in project Ajman at Rashid Diabetes and Research centre (RDRC), Ajman, UAE

8. Parental leave, military service etc.

Parental leave approximately one year 1999 and one year 2003.

9. Third task; interaction with the public and industry:

Member of Ajman project (educational response during development of diabetes care and Research coordinator at Rashid Diabetes and Research Centre in Ajman, United Arab Emirates) in cooperation with Global Health Partner and Skåne Care AB
Speaker and member of advisory board for drug companies (Eli-Lilly, Novartis, Sanofi-Aventis)

10. Awards:

2005 Swedish Endocrinology Association, Best clinical lecture
2007 Sanofi-Aventis/Swedish Diabetes Association, Studies of the effects of anti-diabetes drugs on cardiac function

11. Publications:

1. **Dorkhan M**, Lantz M, Frid A, Groop L, Hallengren B; Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes, *Clinical Endocrinology*, 65, 35-9, 2006
2. **Dorkhan M**, Magnusson M, Frid A, Grubb A, Groop L, Jovinge S; Glycemic and non-glycemic effects of pioglitazone in triple oral therapy in patients with type 2 diabetes mellitus, *Journal of Internal Medicine*, 260, 125-33, 2006
3. **Dorkhan M**, Frid A; A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes, *Vascular Health and Risk Management*, 3, 721-31, 2007
4. **Dorkhan M**, Tripathy D, Malm G, H Asgharian, Tuomi T, Groop L; Independent measures of insulin secretion and insulin sensitivity during the same test; the glucagon-insulin tolerance test (GITT). *Journal of Internal Medicine*, 2008
5. **Dorkhan M**, Dencker M, Frid A. Treatment with pioglitazone induced significant, reversible mitral regurgitation. *Cardiovascular Diabetology*, 2008
6. **Dorkhan M**, Frid A, Groop L. Effects and side effects of adding insulin glargine or pioglitazone to oral anti-diabetic therapy in patients with type 2 diabetes. *Diabetes Research and Clinical Practice*, 2008
7. **Dorkhan M**, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. *Cardiovascular Diabetology*, 2009

Description of research activities and main scientific/methodological competence:

Leadership of ANDiS, regional project aiming to define clinical/genetic characteristics of subgroups of diabetes in southern Sweden.
Treatment of type 2 diabetes, focus on applying methods used in clinical practice in order to delineate guidelines on individualized medicine in the care of patients with type 2 diabetes.